TTK and neoplasm: The combination (Mps1+CDK4/6) also may prove effective in a wider tumor segment in which the underlying oncogenic lesion is the loss of both Rb1 and p53 because these tumors are chromosomally unstable, aggressive, proliferative neoplasms.